替吉奥联合顺铂治疗HER-2阴性胃癌患者的临床疗效和安全性评估  

Clinical efficacy and safety evaluation of Tiggio combined with cisplatin in treatment of patients with HER-2 negative gastric cancer

作　　者：王雪[1] 赵鸿鹰 李文广[1] 张改琴[1] 杨欢[1] WANG Xue;ZHAO Hong-ying;LI Wen-guang;ZHANG Gai-Qin;YANG Huan(Department of Oncology,Xuzhou Tumor Hospital,Xuzhou 221005,China)

机构地区：[1]徐州市肿瘤医院肿瘤内科,徐州医科大学,江苏徐州221005

出　　处：《中国药物应用与监测》2023年第4期226-230,共5页Chinese Journal of Drug Application and Monitoring

基　　金：江苏省卫生健康委员会项目编号(M2022121)。

摘　　要：目的:探究替吉奥联合顺铂化疗对人类表皮生长因子受体-2(HER-2)阴性胃癌患者血清糖类抗原(CA)724、血管内皮生长因子(VEGF)表达的影响。方法:选取80例HER-2阴性胃癌患者(在本院接受治疗),随机分为对照组(40例)和SP组(40例)。其中对照组给予顺铂联合氟尿嘧啶治疗,联合组给予替吉奥联合顺铂治疗。比较两组免疫功能(CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+)),血清CA724、VEGF水平,临床疗效,生存率及不良反应发生率。结果:与治疗前比较,两组治疗后CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+)、血清CA724、VEGF水平均明显降低(P<0.05),且与对照组比较,SP组上述指标明显较低(P<0.05);SP组疾病缓解率(62.50%)明显高于对照组(40.00%)(P<0.05);对患者进行为期2年的随访,对照组患者生存15例,占37.50%;SP组患者生存24例,占60.00%;行Log-rank检验显示,两组累积生存率比较差异有统计学意义(χ^(2)=6.125,P=0.013);两组口腔溃疡、恶心呕吐、白细胞减少及骨髓抑制等不良反应总发生率比较无差异(P>0.05)。结论:替吉奥联合顺铂化疗治疗HER-2阴性胃癌患者可有效调节血清CA724、VEGF水平及免疫功能,提高生存率,安全有效。Objective:To investigate the impacts of tegafur,gimeracil and oteracil porassium capsules combined with cisplatin chemotherapy on the expressions of serum carbohydrate antigen(CA)724 and vascular endothelial growth factor(VEGF)in patients with human epidermal growth factor receptor-2(HER-2)negative gastric cancer.Methods:Eighty patients with HER-2 negative gastric cancer admitted to our hospital were enrolled in this study and randomized into the control group and SP group,with 40 in each.The patients in the control group were treated with cisplatin combined with fluorouracil,and those in the combined group with tegafur,gimeracil and oteracil porassium capsules combined with cisplatin.The immune functions(CD4^(+),CD3^(+),CD4^(+)/CD8^(+)),the levels of serum CA724 and VEGF,clinical efficacy,survival rate and incidence of adverse reactions were compared between the 2 groups.Results:The levels of CD4^(+),CD3^(+),CD4^(+)/CD8^(+),serum CA724 and VEGF in both groups were obviously decreased after treatment than before(P<0.05).As compared to the control group,the CD4^(+),CD3^(+),CD4^(+)/CD8^(+)in SP group were obviously increased,and the levels of serum CA724 and VEGF were obviously decreased in the combined one(P<0.05).The disease remission rate in the combined group(62.50%)was obviously higher than that in the control(40.00%)(P<0.05).The patients were followed up for 2 years,and 15 patients in the control group survived,accounting for 37.50%while 24 patients in SP group survived,accounting for 60.00%.Log-rank test showed that there was a statistically obvious difference in the cumulative survival rate between the two groups(χ^(2)=6.125,P=0.013).However,there was no obvious difference in the overall incidence of adverse reactions such as oral ulcers,nausea and vomiting,leukopenia and bone marrow suppression between the 2 groups(P>0.05).Conclusion:Tegafur,gimeracil and oteracil porassium capsules combined with cisplatin chemotherapy for patients with HER-2 negative gastric cancer can effectively regulate serum CA724,VE

关 键 词：HER-2阴性胃癌 顺铂 替吉奥 糖类抗原724 血管内皮生长因子 

分 类 号：R735.2[医药卫生—肿瘤]